The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.

van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ, Lamberts SW

Clinical endocrinology1 Aug 2005Cited by 46 (Europe PMC)

PMID16060911DOI10.1111/j.1365-2265.2005.02322.xPepBankPUB-16060911

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with acromegaly, octreotide produced higher IGFBP-1 AUC than SOM230 250 microg: 237 versus 163 microg/l/h (P < 0.05).
In plain wordsIn patients with acromegaly, octreotide increased IGFBP-1 more than SOM230 250 microg.
Peptide
Octreotide
Outcome
IncreaseIGFBP-1 AUC versus SOM230 250 microg
Study
n = 12
Comparator
SOM230 250 microg
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · subcutaneous · single injectionAs given in this study (human).
Measurements
IGFBP-1 AUC (0830-1430 h)
237 microg/l/h
after octreotide 100 microg
IGFBP-1 AUC (0830-1430 h)
163 microg/l/h
after SOM230 250 microg
Source sentences
Summary
Circulating IGFBP-1 levels (AUC; 0830-1430 h) compared with CD, increased sharply after OCT (from 48 to 237 microg/l/h; P < 0.001 vs. CD), while SOM230 250 and 100 microg elicited a lower and dose-dependent effect (163 and 90 microg/l/h, respectively, P < 0.05 vs. CD and OCT).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, cross-over, double-blinded proof-of-concept trial in 12 patients with active acromegaly.
Summary · context
Since SRIF analogues are also known to interact with other metabolic pathways, IGF-I, IGFBP-1, glucose and insulin concentrations on the control day (CD) and on treatment days following a single s.c. injection SOM230 100 and 250 microg, were compared to those following OCT 100 microg.
Report a problemFND-1606091104
02HumanRandomized controlled trialEfficacy outcome
In patients with acromegaly, octreotide produced higher IGFBP-1 AUC than SOM230 100 microg: 237 versus 90 microg/l/h (P < 0.05).
In plain wordsIn patients with acromegaly, octreotide increased IGFBP-1 more than SOM230 100 microg.
Peptide
Octreotide
Outcome
IncreaseIGFBP-1 AUC versus SOM230 100 microg
Study
n = 12
Comparator
SOM230 100 microg
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · subcutaneous · single injectionAs given in this study (human).
Measurements
IGFBP-1 AUC (0830-1430 h)
237 microg/l/h
after octreotide 100 microg
IGFBP-1 AUC (0830-1430 h)
90 microg/l/h
after SOM230 100 microg
Source sentences
Summary
Circulating IGFBP-1 levels (AUC; 0830-1430 h) compared with CD, increased sharply after OCT (from 48 to 237 microg/l/h; P < 0.001 vs. CD), while SOM230 250 and 100 microg elicited a lower and dose-dependent effect (163 and 90 microg/l/h, respectively, P < 0.05 vs. CD and OCT).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, cross-over, double-blinded proof-of-concept trial in 12 patients with active acromegaly.
Summary · context
Since SRIF analogues are also known to interact with other metabolic pathways, IGF-I, IGFBP-1, glucose and insulin concentrations on the control day (CD) and on treatment days following a single s.c. injection SOM230 100 and 250 microg, were compared to those following OCT 100 microg.
Report a problemFND-1606091105
03HumanRandomized controlled trialEfficacy outcome
In patients with acromegaly, glucose at 1 h was 4.4 +/- 0.5 mmol/l after octreotide versus 8.3 +/- 0.8 after SOM230 250 microg (P < 0.05).
In plain wordsIn patients with acromegaly, glucose at 1 h was lower after octreotide than after SOM230 250 microg.
Peptide
Octreotide
Outcome
DecreaseGlucose at 1 h versus SOM230 250 microg
Study
n = 12
Comparator
SOM230 250 microg
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
100 microg · subcutaneous · single injectionAs given in this study (human).
Measurements
Glucose 1 h postinjection
4.4 mmol/l
after octreotide 100 microg; reported +/- 0.5
Glucose 1 h postinjection
8.3 mmol/l
after SOM230 250 microg; reported +/- 0.8
Source sentences
Summary
An early rise in glucose levels 1 h postinjection with SOM230 250 microg compared with OCT and CD was observed 8.3 +/- 0.8, 4.4 +/- 0.5 and 4.9 +/- 0.4 mmol/l, respectively: P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, cross-over, double-blinded proof-of-concept trial in 12 patients with active acromegaly.
Summary · context
Since SRIF analogues are also known to interact with other metabolic pathways, IGF-I, IGFBP-1, glucose and insulin concentrations on the control day (CD) and on treatment days following a single s.c. injection SOM230 100 and 250 microg, were compared to those following OCT 100 microg.
Report a problemFND-1606091108
04HumanRandomized controlled trialEfficacy outcome
In patients with acromegaly, insulin was 5.4 +/- 0.4 mU/l after octreotide versus 19 +/- 4 after SOM230 250 microg.
In plain wordsIn patients with acromegaly, insulin was lower after octreotide than after SOM230 250 microg.
Peptide
Octreotide
Outcome
DecreaseInsulin versus SOM230 250 microg
Study
n = 12
Comparator
SOM230 250 microg
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
100 microg · subcutaneous · single injectionAs given in this study (human).
Measurements
Insulin
5.4 mU/l
after octreotide 100 microg; reported +/- 0.4
Insulin
19 mU/l
after SOM230 250 microg; reported +/- 4
Source sentences
Summary
SOM230 250 microg (19 +/- 4 vs. 46 +/- 3 mU/l on CD: P < 0.05), although clearly less potent than OCT (5.4 +/- 0.4 mU/l: P < 0.01 vs. CD), inhibited insulin release.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, cross-over, double-blinded proof-of-concept trial in 12 patients with active acromegaly.
Summary · context
Since SRIF analogues are also known to interact with other metabolic pathways, IGF-I, IGFBP-1, glucose and insulin concentrations on the control day (CD) and on treatment days following a single s.c. injection SOM230 100 and 250 microg, were compared to those following OCT 100 microg.
Report a problemFND-1606091110
05HumanNon-randomized trialEfficacy outcome
In patients with acromegaly, octreotide suppressed free IGF-I at 24 h relative to the control day.
In plain wordsIn patients with acromegaly, octreotide reduced free IGF-I at 24 h compared with the control day.
Peptide
Octreotide
Outcome
DecreaseFree IGF-I at 24 h
Study
n = 12
Comparator
Control day
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · subcutaneous · single injectionAs given in this study (human).
Source sentences
Summary
Free IGF-I levels were suppressed after 24 h by OCT, SOM230 250 and 100 microg, whereas at 48 h only both SOM230 dosages still induced these inhibitory effects.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, cross-over, double-blinded proof-of-concept trial in 12 patients with active acromegaly.
Summary · context
Since SRIF analogues are also known to interact with other metabolic pathways, IGF-I, IGFBP-1, glucose and insulin concentrations on the control day (CD) and on treatment days following a single s.c. injection SOM230 100 and 250 microg, were compared to those following OCT 100 microg.
Report a problemFND-1606091101
06HumanNon-randomized trialEfficacy outcome
In patients with acromegaly, octreotide no longer suppressed free IGF-I at 48 h, unlike both SOM230 doses.
In plain wordsIn patients with acromegaly, octreotide no longer suppressed free IGF-I at 48 h, unlike both SOM230 doses.
Peptide
Octreotide
Outcome
No significant changeFree IGF-I at 48 h
Study
n = 12
Comparator
Control day
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · subcutaneous · single injectionAs given in this study (human).
Source sentences
Summary
Free IGF-I levels were suppressed after 24 h by OCT, SOM230 250 and 100 microg, whereas at 48 h only both SOM230 dosages still induced these inhibitory effects.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, cross-over, double-blinded proof-of-concept trial in 12 patients with active acromegaly.
Summary · context
Since SRIF analogues are also known to interact with other metabolic pathways, IGF-I, IGFBP-1, glucose and insulin concentrations on the control day (CD) and on treatment days following a single s.c. injection SOM230 100 and 250 microg, were compared to those following OCT 100 microg.
Report a problemFND-1606091102
07HumanNon-randomized trialEfficacy outcome
In patients with acromegaly, octreotide increased IGFBP-1 AUC from 48 to 237 microg/l/h (P < 0.001 versus control day).
In plain wordsIn patients with acromegaly, octreotide increased IGFBP-1 compared with the control day.
Peptide
Octreotide
Outcome
IncreaseIGFBP-1 AUC versus control day
Study
n = 12
Comparator
Control day
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · subcutaneous · single injectionAs given in this study (human).
Measurements
IGFBP-1 AUC (0830-1430 h)
48 microg/l/h
control day
IGFBP-1 AUC (0830-1430 h)
237 microg/l/h
after octreotide 100 microg
Source sentences
Summary
Circulating IGFBP-1 levels (AUC; 0830-1430 h) compared with CD, increased sharply after OCT (from 48 to 237 microg/l/h; P < 0.001 vs. CD), while SOM230 250 and 100 microg elicited a lower and dose-dependent effect (163 and 90 microg/l/h, respectively, P < 0.05 vs. CD and OCT).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, cross-over, double-blinded proof-of-concept trial in 12 patients with active acromegaly.
Summary · context
Since SRIF analogues are also known to interact with other metabolic pathways, IGF-I, IGFBP-1, glucose and insulin concentrations on the control day (CD) and on treatment days following a single s.c. injection SOM230 100 and 250 microg, were compared to those following OCT 100 microg.
Report a problemFND-1606091103
08HumanNon-randomized trialEfficacy outcome
In patients with acromegaly, insulin after octreotide was 5.4 +/- 0.4 mU/l versus 46 +/- 3 on the control day (P < 0.01).
In plain wordsIn patients with acromegaly, octreotide reduced insulin compared with the control day.
Peptide
Octreotide
Outcome
DecreaseInsulin versus control day
Study
n = 12
Comparator
Control day
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
100 microg · subcutaneous · single injectionAs given in this study (human).
Measurements
Insulin
5.4 mU/l
after octreotide 100 microg; reported +/- 0.4
Insulin
46 mU/l
control day; reported +/- 3
Source sentences
Summary
SOM230 250 microg (19 +/- 4 vs. 46 +/- 3 mU/l on CD: P < 0.05), although clearly less potent than OCT (5.4 +/- 0.4 mU/l: P < 0.01 vs. CD), inhibited insulin release.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, cross-over, double-blinded proof-of-concept trial in 12 patients with active acromegaly.
Summary · context
Since SRIF analogues are also known to interact with other metabolic pathways, IGF-I, IGFBP-1, glucose and insulin concentrations on the control day (CD) and on treatment days following a single s.c. injection SOM230 100 and 250 microg, were compared to those following OCT 100 microg.
Report a problemFND-1606091109
09HumanObservational studyMechanism
In patients with acromegaly after octreotide, insulin levels did not correlate significantly with IGFBP-1 levels.
In plain wordsIn patients with acromegaly after octreotide, insulin and IGFBP-1 levels had no significant correlation.
Peptide
Octreotide
Outcome
No significant changeInsulin correlation with IGFBP-1
Study
n = 12
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
100 microg · subcutaneous · single injectionAs given in this study (human).
Source sentences
Summary
Neither insulin nor GH levels showed statistically significant correlation with IGFBP-1 levels either after SOM230 or OCT.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, cross-over, double-blinded proof-of-concept trial in 12 patients with active acromegaly.
Summary · context
Since SRIF analogues are also known to interact with other metabolic pathways, IGF-I, IGFBP-1, glucose and insulin concentrations on the control day (CD) and on treatment days following a single s.c. injection SOM230 100 and 250 microg, were compared to those following OCT 100 microg.
Report a problemFND-1606091106
10HumanObservational studyMechanism
In patients with acromegaly after octreotide, GH levels did not correlate significantly with IGFBP-1 levels.
In plain wordsIn patients with acromegaly after octreotide, growth hormone and IGFBP-1 levels had no significant correlation.
Peptide
Octreotide
Outcome
No significant changeGH correlation with IGFBP-1
Study
n = 12
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 microg · subcutaneous · single injectionAs given in this study (human).
Source sentences
Summary
Neither insulin nor GH levels showed statistically significant correlation with IGFBP-1 levels either after SOM230 or OCT.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, cross-over, double-blinded proof-of-concept trial in 12 patients with active acromegaly.
Summary · context
Since SRIF analogues are also known to interact with other metabolic pathways, IGF-I, IGFBP-1, glucose and insulin concentrations on the control day (CD) and on treatment days following a single s.c. injection SOM230 100 and 250 microg, were compared to those following OCT 100 microg.
Report a problemFND-1606091107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.

Summary

Results from this study10

Version history

Subjects

Publication types

MeSH terms